{"id":"esg206","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, ESG206 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly relevant for the treatment of type 2 diabetes.","oneSentence":"ESG206 is a small molecule targeting the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:51:48.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07375524","phase":"PHASE2","title":"A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Escugen Biotechnology Co., Ltd","startDate":"2026-03-01","conditions":"Primary Sjögren Syndrome","enrollment":40},{"nctId":"NCT05822843","phase":"PHASE1","title":"A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies","status":"COMPLETED","sponsor":"Shanghai Escugen Biotechnology Co., Ltd","startDate":"2023-08-02","conditions":"B-cell Lymphoid Malignancies","enrollment":13},{"nctId":"NCT05263739","phase":"PHASE1","title":"A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies","status":"WITHDRAWN","sponsor":"Shanghai Escugen Biotechnology Co., Ltd","startDate":"2025-12","conditions":"B-cell Lymphoid Malignancies","enrollment":""},{"nctId":"NCT06853444","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Shanghai Escugen Biotechnology Co., Ltd","startDate":"2025-05-08","conditions":"Immune Thrombocytopenia (ITP)","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ESG206-2"],"phase":"phase_2","status":"active","brandName":"ESG206","genericName":"ESG206","companyName":"Shanghai Escugen Biotechnology Co., Ltd","companyId":"shanghai-escugen-biotechnology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ESG206 is a small molecule targeting the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}